Kyverna Therapeutics reported one-year clinical data supporting its rare autoimmune CAR-T program, miv-cel, in stiff person syndrome. The company said the results bolster its case for submission to regulators, positioning the candidate as a potential durable autoimmune benefit with a safety profile it describes as unblemished. The update arrives as the autoimmune CAR-T category faces scrutiny after safety setbacks from other players, increasing the emphasis on long-term follow-up, adverse event transparency and durability of disease control. For Kyverna, the readout functions as both scientific validation and a market signal that the approach can be sustained over extended periods in a high-risk population. The company’s communications also highlight how CAR-T development timelines in autoimmune settings increasingly depend on managing risk around neurologic and immune-mediated toxicity signals, not only efficacy endpoints.